Introduction {#sec1-1}
============

Cancer cell lines, in general, are used as a model in testing of anticancer drugs presently used \[[@ref1],[@ref2]\] as well as in the development of new therapies \[[@ref3],[@ref4]\]. There is no bovine cell line of squamous cell carcinoma (SCC) origin. This is probably the first ever attempt to develop a SCC cell line of bovine origin. The horn cancer-based cell line can be used as an *in vitro* model in cancer research to define potential molecular markers as well as for the screening and characterization of cancer therapeutics similar to human lung and breast cancer cell lines \[[@ref5],[@ref6]\]. The results of the research in cancer cell lines can usually be extrapolated to *in vivo* tumors originated from squamous cells. Transcriptomic profiling of the initial passage cells and the SCC tissue was attempted in this study to confirm the initial passage cells represent the SCC tissue at molecular level.

Historically, *in vitro* cultures of SCC of horn (bovine horn core carcinoma \[BHCC\]) have been limited in availability and scope, compared to those from many other organs such as mammary tumors and endometrial cancer cell lines. Cell lines, those derived from metastases, do not span the range of most of cancer phenotypes, and in particular, are not representative of original SCC \[[@ref7]\]. Furthermore, how extensively long-term culture alters the biological properties of cell lines are always of concern \[[@ref8]\]. Adaptation of fresh cancerous tissue specimens which grow *in vitro* as primary cell cultures provides homogeneous cellular material, enriched in tumor cell component \[[@ref7]\] and it also retains phenotypic, transcriptomics profile of the corresponding tissues from which they derive \[[@ref8]-[@ref10]\] at the first passages.

Usually, up regulations of genes are involved in proliferation and metabolism. Cellular activity within a tissue is evinced by the transcriptome at a specific time. Pathophysiology of complex diseases, like cancer, can be evaluated by an unbiased method like genome-wide expression studies \[[@ref10]\]. RNA sequencing (RNA-Seq) analysis is an affordable accurate and comprehensive tool to analyze transcriptome of complementary DNAs (cDNA) using next generation sequencing (NGS), followed by mapping of reads onto the reference genome making it possible to identify introns, exons, their flanking regions and thus providing an opportunity to understand the complexity of eukaryotic transcriptome \[[@ref11]\].

SCC of horn of bovines is a SCC of horn core mucosa with least known genetic landscape, reported only in *Bos indicus*. This causes heavy economic losses due to subsequent metastasis and death of animal. In India, approximately 1% of the cattle population is affected by this tumor \[[@ref12]\], most commonly in working bullocks, sometimes in cows and rarely in bulls, buffaloes, sheep, and goats \[[@ref13]-[@ref16]\]. The incidence of SCC of horns is more frequent in Kankrej breed than other zebu cattle, crossbred or non-descript cattle \[[@ref17]\]. From Sumatra \[[@ref18]\], Brazil \[[@ref19]\], and Iraq \[[@ref20]\] few cases were reported. Till date, the comparison of gene expression profile between cell culture and parental tissue of SCC of horn of bovines has not been performed. The study was designed to compare gene expression profiles in SCC affected horn tissue and primary cell culture derived from that tumor using Ion Torrent PGM sequencing platform.

Materials and Methods {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

Aprroval for research work granted vide approval no. IAEC: 155/2011 of College of Veterinary Science and animal Husbandry, Anand Agricultural Universuty, Anand-388 001, Gujarat.

Tissue collection {#sec2-2}
-----------------

Carcinomatous and normal horn core mucosa were collected during corrective surgery in RNAlater^®^ (Thermo Fisher scientific, Massachusetts, USA) from clinically affected (left horn) and normal (right horn) horn of a Kankrej breed of bullock (age 7 years) from Rajkot, Gujarat, India. Necrotic tissues were not collected. Fresh tissues were cut into pea-sized segments and preserved in:

10% neutral buffered formalin for histopathological studiesRNAlater^®^ (Sigma-Aldrich, St. Louis, USA) for RNA extractionDulbecco's modification of Eagle's medium (DMEM) (50 ml) (Thermo Fisher Scientific, Massachusetts, USA) with penicillin-streptomycin (500 µl) (Thermo Fisher Scientific, Massachusetts, USA) + amphotericin-B (500 µl) (Thermo Fisher Scientific, Massachusetts, USA) and brought to lab at 0-4°C.

Histopathology {#sec2-3}
--------------

Horn SCC tissues were processed for histopathological studies and paraffin-embedded sections were cut at 5-6 µ thickness with section cutting machine (Leica, Germany) and stained with hematoxylin and eosin (H and E) \[[@ref21]\]. The H and E stained sections were observed under light microscope and lesions were observed \[[@ref21]\].

Cell culture {#sec2-4}
------------

After removal of adipose tissue, tumor tissues (at 4°C) were mechanically minced in 1 mm^3^ fragments. Then, the primary culture was established and incubated at 37°C and 5% CO~2~ \[[@ref21]\]. Similarly, tumor tissue explant culture was also performed by standard protocol \[[@ref16]\]. DMEM and Ham's F12 50/50 mix (DMEM-F12) medium was changed twice weekly and split ratio for cells were 1:3 when cells reached up to 90% confluence. Cell morphology was observed in contrast phase, at 40× magnification, by inverted microscope. The cells were sampled at intervals, resuspended in a freezing medium (80% DMEM, 10% fetal bovine serum, and 10% dimethyl sulfoxide), and stored at −80°C at every two passages for cryopreservation.

Differential trypsinization was used for removal of the fibroblasts which detached sooner than the tumor cells. Isolation of pure population of tumor cells was done by plating approximately 10,000 detached cells in 100 mm Petri dishes and following dilution cloning \[[@ref22]\]. These isolated clones were used for RNA-Seq purposes.

Cell proliferation and doubling time assay {#sec2-5}
------------------------------------------

Two counts were performed for each passage, in triplicate. For doubling time analysis, plating of cells in triplicate onto 6-well plates at a concentration of 2.5 × 10^4^ cells/well in DMEM-F12 were done. After 24, 48 and 72 h, cells were collected after trypsinization and counted in a Neubauer chamber. Doubling time (in hour) was calculated as described in a previous study \[[@ref23]\].

RNA isolation {#sec2-6}
-------------

TRIzol (Sigma-Aldrich, St. Louis, USA) method as per manufacturer's instructions was used to isolate RNA from early passage cells of SCC of horns (pooled RNA of passage 2 and 3) and parental SCC tissue.

Preparation of sample and transcriptome procedure {#sec2-7}
-------------------------------------------------

All the protocols starting from mRNA isolation to library preparation were followed as per manufacturer's instructions. The detailed protocol steps can be accessed from Ion Torrent's "Ion Total RNA-Seq Kit" (Part No.: 4467098) using 316 chip.

*In silico* gene expression analysis {#sec2-8}
------------------------------------

Sequence reads were generated from cDNA libraries of early passage cells and parental SCC horn tissue using Ion Torrent PGM chemistry using 316 chips \[[@ref24]\]. Raw sequence reads (\*.fastq files) were checked for quality control in FastQC v0.10.1. To avoid low quality data negatively influencing downstream analysis, the reads were trimmed and low quality sequences were filtered using PRINSEQ-lite version 0.20.2 with default parameters in Linux. This quality checked reads were aligned to the bosTau7.fa build of the cow genome (<http://hgdownloadtest.cse.ucsc.edu/goldenPath/bosTau7/chromosomes/>) using GMAP \[[@ref25]\] and Samtools allowing for unique non-gapped alignments to the genome. The default parameters for the GMAP method were used.

The resultant \*.sam files were converted to \*.bam files with Samtools then \*.sorted.bam files were used in Cufflinks v 2.2.1. The resulting Cufflinks assemblies of all samples were combined together using Cuffcompare v 2.2.1. The differential expression was calculated by Cuffdiff based on transcript abundances \[[@ref26]\]. Cuffdiff v 2.2.1 was then employed on the combined transcripts to identify differentially expressed genes/transcripts.

RNA-Seq data normalization {#sec2-9}
--------------------------

The raw RNA-Seq read counts for cufflinks transcripts were first log~2~ transformed at fragments per kilobase of exon per million reads mapped (FPKM) and then quantile normalized.

Functional annotation {#sec2-10}
---------------------

The genes differentially expressed in SCC horn tissue and the short-term primary culture was selected for functional categorization. The comparisons between expressed genes which produced Cuffdiff output with "Q value" \<0.01 and "OK" marked test status were considered to be differentially expressed. Gene ontology (GO) and pathway analyses of up and down-regulated genes by DAVID database \[[@ref27]\] and PANTHER database \[[@ref28]\] were done, respectively. Gene set analyses were done in terms of biological processes, molecular function, and cellular component. The list of differentially expressed genes having \>5 FPKM value and log~2~ fold change value above 2 (based on FPKM ratio), p=0.05 and false discovery rate (FDR) value 5% were chosen.

Whole transcriptome analysis using NGS will identify several thousands of genes which are deregulated in number of cancer-related pathways. Since the depth of sequencing for each gene varies because of inherent methodology involved in NGS, it is globally accepted protocol to validate data obtained by this methodology via randomly selecting few of the genes through quantitative real-time polymerase chain reaction (PCR) \[[@ref29],[@ref30]\]. Since it is practically impossible to validate all of the genes found in NGS-based study as well as it is economically non-feasible approach to study all identified genes, we have followed standard procedure to validate NGS data by selecting randomly selected sufficiently large set of transcripts and proved concordance of expression pattern using quantitative real-time PCR (Data not shown).

Results {#sec1-3}
=======

Histopathology of SCC tissue {#sec2-11}
----------------------------

The tumor cells were tightly cohesive, featured with moderately high to abundant eosinophilic cytoplasm. The nucleus to cytoplasmic ratio was potentially increased with nuclei showing frequent prominent nucleoli. Mitotic activity was abundant including atypical forms such as ring and tripolar configurations. Intercellular bridges were focally present. Keratinization of individual epithelial cells ([Figure-1a](#F1){ref-type="fig"}) and pleomorphic epithelial cells with enlarged nuclei ([Figure-1b](#F1){ref-type="fig"}) were seen. Histopathology confirmed SCC of the horn core epithelium.

![(a) Keratinization of individual horn squamous cell carcinoma (SCC) epithelial cells of parental tissue as seen in H and E stain at 100×, (b) pleomorphic horn SCC cells with nucleolar polymorphism of parental tissue as seen in H and E stain at 100×.](VetWorld-10-38-g001){#F1}

Isolation of SCC horn epithelial cells {#sec2-12}
--------------------------------------

Primary monolayer culture with finite mitotic lifespan (SCC early passage cells) was established from the bullock affected with SCC of horn ([Figure-2](#F2){ref-type="fig"}) following the enzymatic disaggregation methods as described earlier \[[@ref22]\]. By the first week, tumor cells were seen rounding up and growing throughout the T-25/T-75 flask ([Figure-3](#F3){ref-type="fig"}) among the normal stromal fibroblasts that grew in parallel.

![Primary monolayer culture of horn squamous cell carcinoma cells at 40×.](VetWorld-10-38-g002){#F2}

![Rounded up horn squamous cell carcinoma malignant early passage cells on day 7 at 40×.](VetWorld-10-38-g003){#F3}

Growth curve and population doubling time analysis {#sec2-13}
--------------------------------------------------

Population doubling time ascertained around 28.1 h ([Figure-4](#F4){ref-type="fig"}), and cell viability ranged from 85% to 94%. The culture success rate was 90%.

![Growth curves of horn squamous cell carcinoma (bovine horn core carcinoma) early passage cells.](VetWorld-10-38-g004){#F4}

Transcriptomic comparison between SCC horn tissue and its early passage cells {#sec2-14}
-----------------------------------------------------------------------------

The total number of genes differentially overexpressed in SCC horn tissue were 717 (8.40% of total genes expressed) compared to early passage cells; 150 genes (1.76% of total genes expressed) were differentially up-regulated which had more than 2-fold Log~2~ value with maximum value of 6.03-fold change. There were 746 genes (8.74% of total genes expressed) which had differential over-expression in early passage cells than SCC horn tissue, 248 genes (2.90% of total genes expressed) had more than 2-fold log~2~ value with maximum Log~2~ value 7.02. In this comparison, 5219 genes (\~38% of total genes no., i.e., 14513 no.) showed no expression at the terms of FPKM in both the samples 1600 genes had more than 5 FPKM value in early passage cells.

Genes overexpressed in SCC early passage cells and SCC horn tissue {#sec2-15}
------------------------------------------------------------------

Density plot and dispersion plot were derived for this comparison, respectively. Density plot assessed the distributions of FPKM scores across samples. Among the differentially expressed genes maximum genes had FPKM value between Log~10~ 1 and Log~10~ 2. Distribution of genes in SCC horn tissue ranged from Log~10~ 0.2 to Log~10~ 3.7 and for early passage SCC cells, it was Log~10~ 0.7 to Log~10~ 3.7. Dispersion plot showed normal dispersion of genes across samples. N-Myc downstream regulated 1, integrin alpha 6, TP53 apoptosis effector (PERP), eukaryotic translation initiation factor 4 A1 (A1EIF4A1), desmoplakin, etc., genes were up-regulated (up-to 2-fold FPKM value) in SCC horn tissue compared to SCC early passage cells. Up-regulated genes (up to 2-fold FPKM value) in horn SCC early passage cells compared to parental tissue were coiled-coil domain containing 69 (CCDC69), CCDC94, Sec61 gamma subunit (SEC61G), Paladin, *Hedgehog* (Hh) receptor patched homolog 1 (PTCH1), Armadillo repeat containing X-linked 2 and thioredoxin, etc.

GO category of the genes differentially expressed above 2 log~2~ fold change in SCC early passage cells compared to SCC horn tissue to be of calcium channel activity, calcium ion binding, protein phosphatase Type 2A activity and extracellular matrix (ECM) binding as per DAVID database ([Table-1](#T1){ref-type="table"}). The genes which were up-regulated in SCC horn tissue compared to its early passage cells showed major histocompatibility complex (MHC) Class I protein binding, MHC protein binding, procollagen proline 4-dioxygenase activity, peptidyl-proline dioxygenase activity, procollagen-proline dioxygenase activity, and protein disulfide isomerase activity.

###### 

KEGG pathway of genes up in SCC early passage cells significantly over SCC horn tissue.

  KEGG pathway                          p value    Genes   Fold change   Fold enrichment   FDR
  ------------------------------------- ---------- ------- ------------- ----------------- ----------
  bta04350:TGF-beta signaling pathway   0.031289   MAPK1   +2.01994      4.113924          29.86879
  ROCK2                                 +2.16513                                           
  TGFBR1                                +2.03972                                           
  PPP2CB                                +2.30283                                           
  THBS1                                 +3.95799                                           
  bta03010:Ribosome                     0.037987   RPL32   +2.62569      3.869048          35.09439
  RPL23                                 +3.21069                                           
  RPS17                                 +3.94767                                           
  RPL3                                  +3.20979                                           
  RPL24                                 +2.62553                                           
  bta05416:Viral myocarditis            0.06468    SGCG    +3.62476      4.262295          52.58867
  CASP9                                 +2.03964                                           
  MYH11                                 +3.03959                                           
  ITGB2                                 +3.03967                                           
  bta05212:Pancreatic cancer            0.080806   VEGFC   +2.20969      3.880597          60.95311
  MAPK1                                 +2.01994                                           
  CASP9                                 +2.03964                                           
  TGFBR1                                +2.03972                                           
  bta04114:Oocyte meiosis               0.082876   CCNE2   +2.81728      2.981651          61.92363
  MAPK1                                 +2.01994                                           
  PPP2CB                                +2.30283                                           
  PPP2R5E                               +2.13926                                           
  ITPR2                                 +2.03959                                           
  bta05200:Pathways in cancer           0.086841   CCNE2   +2.81728      1.930693          63.72096
  VEGFC                                 +2.20                                              
  MAPK1                                 +2.01994                                           
  PIAS4                                 +5.08415                                           
  CASP9                                 +2.03964                                           
  TGFBR1                                +2.03972                                           
  MET                                   +2.03961                                           
  FGF10                                 +3.62461                                           
  PTCH1                                 +6.20952                                           
  bta05010:Alzheimer's disease          0.089018   MAPK1   +2.01994      2.484076          64.67474
  NDUFS5                                +5.6258                                            
  NDUFB6                                +3.62546                                           
  CASP9                                 +2.03964                                           
  COX5A                                 +2.04022                                           
  ITPR2                                 +2.03959                                           
  bta04360:Axon guidance                0.094055   MAPK1   +2.01994      2.850877          66.79443
  ROCK2                                 +2.16513                                           
  MET                                   +2.03961                                           
  NTN4                                  +5.94653                                           
  SEMA3C                                +2.62465                                           

KEGG=Kyoto Encyclopedia of Genes and Genomes, SCC=Squamous cell carcinoma, TGF=Transforming growth factor, FDR=False discovery rate, CASP9=Caspase 9, PPP2R5E=Protein phosphatase 2 regulatory subunit B epsilon

The percentage of genes which showed up-regulation in SCC horn tissue than SCC early passage cells was 1.76%. Genes up-regulated (≥2-fold) in SCC horn tissue as compared to horn SCC early passage cells were involved in biogenesis, apoptotic response and response to stimulus in biological processes; structural molecular activity and translation regulator activity in molecular function; cell part, organelle and macromolecular complex in cellular component and the up-regulated genes (≥2-fold) in horn SCC early passage cells were involved in cellular process, metabolic process, biological regulation in biological processes; catalytic activity, enzyme regulator activity, binding in molecular function; membrane, extracellular region in cellular component as per PANTHER database.

There was no pathway in 5 FDR limit, but the lowest FDR value was found at transforming growth factor (TGF) beta signaling pathway and ribosomal pathway for differentially up-regulated genes in SCC early passage cells compared to SCC horn tissue in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways ([Table-2](#T2){ref-type="table"}). Surprisingly, most of the genes which showed top fold change (within first 20) were not detected by DAVID during pathway analysis. Focal adhesion, ECM-receptor interaction, thyroid cancer, and pathways in cancer were shown by the genes which were up-regulated in SCC horn tissue than SCC early passage cells ([Table-3](#T3){ref-type="table"}).

###### 

KEGG pathway analysis of significantly up regulated genes in SCC horn tissue in comparison to SCC early passage cells.

  KEGG pathway                                   p value    Genes      Fold change   Fold enrichment   FDR
  ---------------------------------------------- ---------- ---------- ------------- ----------------- -------------
  bta04510:Focal adhesion                        0.003554   CDC42      −3.18266      3.489795918       3.85308
  ITGA6                                          −5.25806                                              
  ILK                                            −2.2332                                               
  COL6A2                                         −3.64219                                              
  PDGFRA                                         −2.10337                                              
  COL1A1                                         −2.81067                                              
  PPP1CB                                         −4.46812                                              
  THBS2                                          −2.81836                                              
  CTNNB1                                         −2.95534                                              
  bta04512:ECM-receptor interaction              0.020151   CD44       −2.84292      4.704761905       20.12056515
  ITGA6                                          −5.25806                                              
  COL6A2                                         −3.64219                                              
  COL1A1                                         −2.81067                                              
  THBS2                                          −2.81836                                              
  bta05216:Thyroid cancer                        0.050381   NCOA4      −2.01925      8.142857143       43.47494112
  MYC                                            −3.83476                                              
  CTNNB1                                         −2.95534                                              
  bta05200:Pathways in cancer                    0.058738   HSP90AB1   −2.36404      2.096181047       48.72805735
  CDC42                                          −3.18266                                              
  HSP90AA1                                       −2.39775                                              
  ITGA6                                          −5.25806                                              
  NCOA4                                          −2.01925                                              
  PDGFRA                                         −2.10337                                              
  MYC                                            −3.83476                                              
  STAT3                                          −3.82663                                              
  CTNNB1                                         2.95534                                               
  bta05412:ARVC                                  0.06167    ITGA6      −5.25806      4.342857143       50.4635378
  DSP                                            −4.84482                                              
  GJA1                                           −3.61259                                              
  CTNNB1                                         −2.95534                                              
  bta04612:Antigen processing and presentation   0.066334   HSP90AB1   −2.36404      4.213219616       53.11403035
  HSP90AA1                                       −2.39775                                              
  PDIA3                                          −2.03351                                              
  HSPA8                                          −2.40875                                              
  bta03040:Spliceosome                           0.089962   PRPF8      −4.3062       2.892271663       64.66578307
  SNRNP200                                       −3.32965                                              
  DDX5                                           −2.27017                                              
  HSPA8                                          −2.40875                                              
  HNRNPU                                         −3.78478                                              

KEGG=Kyoto encyclopedia of genes and genomes, SCC=Squamous cell carcinoma, ARVC=Arrhythmogenic right ventricular cardiomyopathy, FDR=False discovery rate, ITGA6=Integrin alpha 6, ECM=Extracellular matrix

###### 

GO of genes up regulated (≥2-fold) in SCC early passage cells compared to SCC horn tissue via DAVID.

  Term                                                                        Count   FDR        \%         p value
  --------------------------------------------------------------------------- ------- ---------- ---------- ----------
  GO:0046872\~metal ion binding                                               47      5.388398   21.17117   0.004134
  GO:0043169\~cation binding                                                  47      6.774957   21.17117   0.005233
  GO:0043167\~ion binding                                                     47      8.187385   21.17117   0.006369
  GO:0019992\~diacylglycerol binding                                          3       25.30314   1.351351   0.021584
  GO:0050840\~ECM binding                                                     3       25.30314   1.351351   0.021584
  GO:0000287\~magnesium ion binding                                           7       34.49892   3.153153   0.031151
  GO:0019838\~growth factor binding                                           4       34.68459   1.801802   0.031356
  GO:0015405\~P-P-bond-hydrolysis driven transmembrane transporter activity   5       47.96599   2.252252   0.047687
  GO:0015399\~primary active transmembrane transporter activity               5       47.96599   2.252252   0.047687
  GO:0008289\~lipid binding                                                   7       60.62826   3.153153   0.067344
  GO:0005262\~calcium channel activity                                        3       74.51316   1.351351   0.097192
  GO:0005543\~phospholipid binding                                            4       75.25716   1.801802   0.099191

Count denotes gene count. GO=Gene ontology, SCC=Squamous cell carcinoma, FDR=False discovery rate, ECM=Extracellular matrix

Genes up-regulated in SCC early passage cells compared to SCC horn tissue were involved in fibroblast growth factor signaling pathway, wnt signaling pathway, vascular endothelial growth factor signaling pathway, apoptosis signaling pathway and p53 signaling, epidermal growth factor receptor, cell cycle, inflammatory pathways mediated by chemokine and cytokine, etc., as per PANTHER database.

KEGG pathway of all genes, expressed in SCC early passage cells showed to be involved in focal adhesion, transforming growth factor TGF-beta signaling pathway, ubiquitin mediated proteolysis, pathways in cancer, prostate cancer mechanism within 5 FDR value ([Table-4](#T4){ref-type="table"}). KEGG pathways such as thyroid cancer, focal adhesion, small cell lung cancer, pathways in cancer, prostate cancer and spliceosome were shown to be involved when all the common genes (≥5 FPKM) between SCC horn tissue and SCC early passage cells compared in DAVID ([Table-5](#T5){ref-type="table"}). To unveil the genes involved in horn cancer pathogenesis, both *in-vivo* and *in-vitro* genes were mined from common pathways up to 5 FDR ([Table-6](#T6){ref-type="table"}).

###### 

KEGG pathway of all genes expressing ≥5 FPKM in SCC early passage cells.

  Term                                                   Count   FDR        \%         p value
  ------------------------------------------------------ ------- ---------- ---------- ----------
  bta04510:Focal adhesion                                48      4.06E-06   3.292181   3.33E-09
  bta04810:Regulation of actin cytoskeleton              40      0.042391   2.743484   3.47E-05
  bta04350:TGF-beta signaling pathway                    22      0.0641     1.508916   5.25E-05
  bta04512:ECM-receptor interaction                      21      0.091836   1.440329   7.52E-05
  bta04520:Adherens junction                             18      0.596801   1.234568   4.90E-04
  bta04120:Ubiquitin mediated proteolysis                28      0.923001   1.920439   7.59E-04
  bta05010:Alzheimer's disease                           30      2.493014   2.057613   0.002065
  bta03010:Ribosome                                      19      3.336116   1.303155   0.002775
  bta05200:Pathways in cancer                            49      3.410855   3.360768   0.002838
  bta05215:Prostate cancer                               18      7.802359   1.234568   0.00663
  bta05016:Huntington's disease                          30      7.998577   2.057613   0.006803
  bta04670:Leukocyte transendothelial migration          22      8.071079   1.508916   0.006867
  bta04114:Oocyte meiosis                                21      12.05085   1.440329   0.01046
  bta00640:Propanoate metabolism                         9       15.5853    0.617284   0.013778
  bta03050:Proteasome                                    11      17.36369   0.754458   0.015496
  bta04270:Vascular smooth muscle contraction            20      17.64442   1.371742   0.015771
  bta04530:Tight junction                                22      19.73693   1.508916   0.017843
  bta03040:Spliceosome                                   22      19.73693   1.508916   0.017843
  bta05412:ARVC                                          14      20.06711   0.960219   0.018174
  bta05211:Renal cell carcinoma                          14      20.06711   0.960219   0.018174
  bta04540:Gap junction                                  16      20.36185   1.097394   0.018471
  bta05212:Pancreatic cancer                             14      24.78525   0.960219   0.023053
  bta05012:Parkinson's disease                           22      28.40347   1.508916   0.02699
  bta05210:Colorectal cancer                             16      31.81445   1.097394   0.030871
  bta05414:Dilated cardiomyopathy                        15      32.4247    1.028807   0.031584
  bta04360:Axon guidance                                 20      32.69897   1.371742   0.031907
  bta04110:Cell cycle                                    21      35.81972   1.440329   0.035663
  bta05410:HCM                                           14      38.80693   0.960219   0.03942
  bta04150:mTOR signaling pathway                        11      39.72862   0.754458   0.040613
  bta05222:Small cell lung cancer                        15      40.92982   1.028807   0.042193
  bta04720:Long-term potentiation                        12      43.26753   0.823045   0.045355
  bta04142:Lysosome                                      19      48.66196   1.303155   0.053134
  bta05213:Endometrial cancer                            10      55.76984   0.685871   0.064618
  bta04666:Fc gamma R-mediated phagocytosis              15      59.04418   1.028807   0.070491
  bta00520:Amino sugar and nucleotide sugar metabolism   9       60.46497   0.617284   0.073175
  bta05220:Chronic myeloid leukemia                      13      69.07887   0.891632   0.091639
  bta00190:Oxidative phosphorylation                     20      70.92517   1.371742   0.096207

Count denotes gene count. ARVC=Arrhythmogenic right ventricular cardiomyopathy, KEGG=Kyoto encyclopedia of genes and genomes, SCC=Squamous cell carcinoma, HCM=Hypertrophic cardiomyopathy, FPKM=Fragments per kilobase of exon per million, FDR=False discovery rate, ECM=Extracellular matrix

###### 

KEGG pathway of all common genes (≥5 FPKM) in between SCC horn tissue and SCC early passage cells.

  Term                                            Count   FDR        \%         p value
  ----------------------------------------------- ------- ---------- ---------- -------------
  bta04510:Focal adhesion                         32      2.52E-06   4.878049   2.12E-09
  bta04810:Regulation of actin cytoskeleton       26      0.014261   3.963415   1.20E-05
  bta04512:ECM-receptor interaction               15      0.027243   2.286585   2.30E-05
  bta05200:Pathways in cancer                     31      0.450733   4.72561    3.81E-04
  bta05215:Prostate cancer                        13      1.366688   1.981707   0.00115989
  bta05412:ARVC                                   11      1.968263   1.676829   0.00167511
  bta04670:Leukocyte transendothelial migration   15      2.062266   2.286585   0.001755881
  bta04520:Adherens junction                      11      2.482973   1.676829   0.002118237
  bta04120:Ubiquitin mediated proteolysis         15      10.18146   2.286585   0.009015052
  bta04530:Tight junction                         14      11.1892    2.134146   0.009957604
  bta03040:Spliceosome                            14      11.1892    2.134146   0.009957604
  bta04350:TGF-beta signaling pathway             10      21.36772   1.52439    0.020069312
  bta05213:Endometrial cancer                     7       35.30036   1.067073   0.036055226
  bta05216:Thyroid cancer                         5       40.50522   0.762195   0.04284919
  bta05414:Dilated cardiomyopathy                 9       41.73228   1.371951   0.044529994
  bta00310:Lysine degradation                     6       44.89775   0.914634   0.049020477
  bta05211:Renal cell carcinoma                   8       45.27855   1.219512   0.049576494
  bta04540:Gap junction                           9       45.96247   1.371951   0.050584067
  bta04110:Cell cycle                             12      47.42947   1.829268   0.052785299
  bta05222:Small cell lung cancer                 9       48.09441   1.371951   0.053801616
  bta05010:Alzheimer's disease                    14      53.2995    2.134146   0.062196631
  bta05210:Colorectal cancer                      9       56.59508   1.371951   0.067966842
  bta03010:Ribosome                               9       56.59508   1.371951   0.067966842
  bta05410:HCM                                    8       61.65301   1.219512   0.077654962
  bta04720:Long-term potentiation                 7       64.27834   1.067073   0.083155068
  bta04722:Neurotrophin signaling pathway         11      64.64354   1.676829   0.0839493

Count denotes gene count. HCM=Hypertrophic cardiomyopathy, FDR=False discovery rate, KEGG=Kyoto encyclopedia of genes and genomes, FPKM=Fragments per kilobase of exon per million, SCC=Squamous cell carcinoma, TGF=Transforming growth factor, ARVC=Arrhythmogenic right ventricular cardiomyopathy

###### 

Genes common in pathways up to 5 FDR between SCC horn tissue and SCC early passage cells.

  KEGG pathway term                               FDR           Genes
  ----------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  bta04510:Focal adhesion                         2.5165\*E06   TLN1, COL3A1, ITGB1, CTNNB1, MYL9, VCL, ACTG1, CDC42, ITGAV, ILK, COL6A2, COL6A1, THBS2, PIK3R2, FN1, ACTB, COL4A1, ACTN4, PPP1CB, FLNB, FLNA, LAMA4, PPP1CA, CCND1, ITGA6, ITGA5, JUN, COL1A2, PDGFRA, RAP1A, PDGFRB, COL1A1, CRK
  bta04810:Regulation of actin cytoskeleton       0.0142        RDX, PIP5K1A, ITGB1, MYL9, VCL, ACTG1, CDC42, EZR, GSN, ITGAV, MSN, FGF2, FN1, APC, PIK3R2, ACTB, ACTN4, PPP1CB, ARPC1A, PPP1CA, ITGA6, ITGA5, CFL1, PDGFRA, PDGFRB, CRK, PIP4K2C
  bta04512:ECM-receptor interaction               0.0272        COL4A1, COL3A1, ITGB1, SDC1, LAMA4, ITGA6, CD44, ITGA5, ITGAV, COL6A2, COL1A2, COL6A1, COL1A1, THBS2, FN1
  bta05200:Pathways in cancer                     0.4507        HSP90AB1, TFG, MMP2, ITGB1, CTNNB1, CDC42, ITGAV, MYC, FGF2, FN1, APC, PIK3R2, COL4A1, HSP90AA1, EPAS1, CREBBP, SMAD4, CTNNA1, STAT3, LAMA4, HSP90B1, CCND1, CDKN1A, HIF1A, ITGA6, NCOA4, JUN, PDGFRA, PDGFRB, JAK1, CRK
  bta05215:Prostate cancer                        1.3666        HSP90AB1, HSP90AA1, CREBBP, CTNNB1, CCND1, HSP90B1, CDKN1A, ATF4, PDGFRA, CREB3L2, CREB3L1, PDGFRB, PIK3R2
  bta05412:ARVC                                   1.9682        ACTB, ACTG1, ACTN4, ITGA6, ITGA5, ITGAV, LMNA, DSP, GJA1, CTNNA1, ITGB1, CTNNB1
  bta04670:Leukocyte transendothelial migration   2.0622        ACTB, ACTN4, GNAI2, GNAI1, CTNNA1, MMP2, ITGB1, VCL, MYL9, CTNNB1, ACTG1, CDC42, EZR, RAP1A, MSN, PIK3R2
  bta04520:Adherens junction                      2.4829        ACTB, ACTG1, CDC42, PVRL1, ACTN4, PTPRF, CREBBP, SMAD4, CTNNA1, SNAI2, VCL, CTNNB1

ARVC=Arrhythmogenic right ventricular cardiomyopathy, FDR=False discovery rate, KEGG=Kyoto Encyclopedia of Genes and Genomes, SCC=Squamous cell carcinoma, ECM=Extracellular matrix

Genes that were uniquely expressed in SCC early passage cells as compared to SCC horn tissue showed involvement in metabolic and cellular process in biological processes; binding, catalytic activity in molecular function; heterotrimeric G protein signaling G~i~ alpha pathway, Huntington disease, endothelin signaling pathway, angiogenesis, interleukin signaling pathway, etc., in pathway as per PANTHER database.

High proliferative and antiapoptotic potential are related to the up-regulation of growth hormone receptor and calmodulins \[[@ref31]\]. The top 20 genes which were found to be up-regulated in SCC early passage cells in comparison to SCC horn tissue were investigated to have roles in other cancers as well as SCC in human and domestic animals ([Table-7](#T7){ref-type="table"}) \[[@ref32]-[@ref61]\] and vice versa ([Table-8](#T8){ref-type="table"}) \[[@ref62]-[@ref95]\].

###### 

Functions of highly expressed genes in SCC early passage cells in comparison to SCC horn tissue.

  Gene ID (ENSBTAG)   Gene title   Name                                                                                 FPKM EP   FPKM HCT   Log~2~ fold change   Roles and implications in cancer of human and other
  ------------------- ------------ ------------------------------------------------------------------------------------ --------- ---------- -------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  00000002834         CCDC69       Coiled-coil domain containing 69                                                     318.123   2.3446     +7.084               Expressed in various cancer cell lines such as HeLa, U2OS and MDA-MB-231, exogenous expression of CCDC69 in HeLa cells destabilized microtubules and disrupted the formation of bipolar mitotic spindles \[[@ref32]\]
  00000012830         CCDC94       Coiled-coil domain containing 94                                                     842.151   10.503     +6.325               Avoids DNA damaging apoptosis in zebra-fish \[[@ref33]\]
  00000014971         SEC61G       Sec61 gamma subunit                                                                  4614.43   62.285     +6.211               Proto-oncogene required for tumor cell survival in GBM, involved in the cytoprotective ER stress--adaptive response to the tumor microenvironment \[[@ref34]\]
  00000008583         KIAA1274     Paladin                                                                              207.836   2.808      +6.209               Vascular-restricted expression in human brain, astrocytoma, and glioblastomas. Paladin expression is reactivated during pathological tumor angiogenesis in the - adult \[[@ref35]\]
  00000048213         PTCH1        Hh receptor patched homolog 1, Uncharacterized protein                               92.8954   1.2552     +6.209               Inversely correlated with the metastatic potential of colon cancer cell lines, high expression associated with low Hh signaling \[[@ref36]\]
  00000003183         NTN4         Netrin 4                                                                             123.963   2.010      +5.946               Anti angiogenic effect, over expression could decrease tumor growth \[[@ref37]\]
  00000010232         NDUFS5       NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15 kDa (NADH-coenzyme Q reductase)   1206.46   24.433     +5.625               Highly expressed in endometrial cancer \[[@ref38],[@ref85]\]
  00000019417         ARMCX2       Armadillo repeat containing, X-linked 2                                              145.59    2.950      +5.624               Might have a role in tumor suppression, role in development and tissue integrity \[[@ref39]\]
  00000021158         SATB1        SATB homeobox 1                                                                      161.255   3.7353     +5.431               High levels of SATB1 expression facilitate CRC and are associated with poor prognosis, promotes breast cancer metastasis, EMT marker in prostrate cancer \[[@ref40]\]
  00000003130         CHRNA3       Cholinergic receptor, nicotinic, alpha 3 (neuronal)                                  1615.84   43.60      +5.211               Polymorphism associated with high chance for NSCLC \[[@ref41],[@ref85]\]
  00000017633         EIF1AX       Eukaryotic translation initiation factor 1A, X linked                                509.347   13.759     +5.210               Mutation is having protective role in uveal melanoma, over expressed in metastatic prostate cancer \[[@ref42],[@ref43]\]
  00000002428         PPA2         Pyrophosphatase (inorganic) 2                                                        255.495   6.903      +5.209               Significantly increased in LNMPCa tissues, supplies increased energy requirement in metastasis - cells \[[@ref44],[@ref45]\]
  00000000753         PIAS4        Protein inhibitor of activated STAT, 4                                               582.593   17.174     +5.084               Necessary for proficient DNA repair of DSBs, promotes BRCA1 SUMOylation and DNA - repair \[[@ref46],[@ref47]\]
  00000013081         PSPH         Phosphoserine phosphatase                                                            516.471   17.942     +4.847               Up-regulated in CRC, increased expression in non-small-cell lung cancer corresponds to clinical response. Suppression inhibited proliferation, tumor formation of MDAMB-468 and MCF10 cells respectively \[[@ref48],[@ref49]\]
  00000002953         TXN          Thioredoxin                                                                          3783.39   136.25     +4.795               Promote cell growth, induces VEGF, PTEN, angiogenesis and inhibit apoptosis in tumor - cells \[[@ref50],[@ref51]\]
  00000015522         MRPS31       Mitochondrial ribosomal protein S31                                                  310.988   12.604     +4.624               Up-regulated in human breast cancer, CRC and found in 77% of all types of cancer \[[@ref52],[@ref53],[@ref85]\]
  00000045742         C5H12orf75   Chromosome 12 open reading frame 75                                                  148.477   6.018      +4.624               Highly expressed in granulosa cells and membrane associated granulosa cells before ovulation in cattle \[[@ref54]\]
  00000009405         TRPC4        Transient receptor potential cation channel, subfamily C, member 4                   51.582    2.091      +4.624               Highly expressed in NSCLC, LNCaP cells activating store operated channel calcium influx - factor \[[@ref55],[@ref56]\]
  00000008636         PDE4B        Phosphodiesterase 4B, cAMP-specific                                                  41.5034   1.6824     +4.624               Highly expressed in diffuse large BCL, expression of it avoids CAMP mediated apoptosis. Induces angiogenesis and cell proliferation in lung cancer cell line \[[@ref57],[@ref58]\]
  00000008294         KCNJ2        Potassium inwardly-rectifying channel, subfamily J, member 2                         35.2224   1.4278     +4.624               Expressed in medulloblastoma with poor clinical outcome, avoids apoptosis and induces cell proliferation in oral cancer also. Increased expression in papillary thyroid cancer \[[@ref59]-[@ref61]\]

EP=SCC early passage cells, HCT=SCC horn tissue, CAMP=Cyclic adenosine monophosphate, SCC=Squamous cell carcinoma, CCDC69=Coiled-coil domain containing 69, ER=Endoplasmic reticulum, GBM=Glioblastoma multiforme, Hh=Hedgehog, NADH=Nicotinamide adenine dinucleotide, CRC=Colorectal cancer, EMT=Epithelial mesenchymal transition, NSCLC=Non--Small Cell Lung Cancer, LNM=Lymph node metastasis, VEGF=Vascular endothelial growth factor, BCL=B-cell lymphoma, FPKM=Fragments per kilobase of exon per million

###### 

Functions of highly expressed genes in SCC horn tissue in comparison to SCC early passage cells.

  Gene ID (ENSBTAG)   Gene title   Name                                                                                     FPKM HCT   FPKM EP   Log~2~ fold change   Roles and implications in cancer of human and other
  ------------------- ------------ ---------------------------------------------------------------------------------------- ---------- --------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  00000000711         NDRG1        N-Myc downstream regulated 1                                                             2001.28    30.4749   −6.03715             Regulated by androgens, acts as metastasis suppressor and negatively correlated with it, found to be down regulated in various cancers, prostate cancer \[[@ref62],[@ref63]\]
  00000017266         ITGA6        Integrin, alpha 6                                                                        835.447    21.8316   −5.2580              Prostate tumors persistently express ITGA6, linked to increased tumor cell invasion, migration, and metastasis. Increased adhesion in AML - cells \[[@ref64],[@ref65]\]
  00000020097         PERP         PERP, TP53 apoptosis effector                                                            1624.07    47.026    −5.11001             Tumor suppressor. Loss induces tumorigenesis, cell survival, and desmosome loss by enhancing inflammatory set of genes in - SCCs \[[@ref66],[@ref67]\]
  00000000132         EIF4A1       Eukaryotic translation initiation factor 4A1                                             1613.66    54.0897   −4.8988              Associated with highly metastasizing melanoma. Overexpression is an early marker for metastasizing hepatocellular carcinoma and NSCLC \[[@ref68],[@ref69]\]
  00000015106         DSP          Desmoplakin                                                                              1837.68    63.9491   −4.8448              Loss of desmoplakin, a cell adhesion molecule, has been implicated in breast cancer metastasis \[[@ref70]\]
  00000047330         FABP5        Fatty acid binding protein 5 (psoriasis associated)                                      1255.27    51.7861   −4.5992              Involved in cell survival and growth, enhances cell proliferation and anchorage-independent growth in prostate and breast cancer - cells \[[@ref71],[@ref72]\]
  00000012447         PPP1CB       Protein phosphatase 1, catalytic subunit, beta isozyme                                   764.459    34.5396   −4.4681              Enhances proliferation and colony formation in leukemia cell line, expressed in 55 cancer cell lines \[[@ref73],[@ref74]\]
  00000010365         SQRDL        Sulphide quinone reductase-like (yeast)                                                  1206.17    57.2255   −4.3976              Under expressed in ductal breast carcinoma, but down regulation reduce cell growth and induce apoptosis in breast cancer cell line \[[@ref75],[@ref76]\]
  00000011969         HSPB1        Heat shock 27 kDa protein 1                                                              2770.43    137.28    −4.3349              Involved in DNA repair, recombination, anti-apoptotic activity in HeLa cells, in most of human cancers, high levels indicate presence of metastatic tissues. Low levels are associated with resistance \[[@ref77],[@ref78]\]
  00000011488         PRPF8        PRP8 pre-mRNA processing factor 8 homolog (*S. cerevisiae*)                              230.594    11.6561   −4.3062              Associated with spliceosome pathway, tumor suppressor in myeloid malignancies \[[@ref79],[@ref80]\]
  00000012927         ALDOA        Aldolase A, fructose-bisphosphate, mRNA                                                  1162.91    60.5281   −4.2639              Promote lung cancer metastasis, invasion capability \[[@ref81],[@ref82]\]
  00000015107         SLC16A1      Solute carrier family 16, member 1 (monocarboxylic acid transporter 1)                   465.287    28.411    −4.0336              Positively associated with cell survival, negatively with mir-124 in medulloblastoma \[[@ref83]\]
  00000021035         CTSK         Cathepsin K, mRNA                                                                        917.7      56.0406   −4.0334              Inconsistent expression in horn cancer tissue in bovine, involved in Hh signaling and pre-osteoclast to osteoclast differentiation in breast cancer \[[@ref84],[@ref86]\]
  00000010793         CCDC80       CCDC80, mRNA                                                                             393.218    24.1296   −4.0264              Tumor suppressor, down regulated in thyroid carcinomas \[[@ref87]\]
  00000013315         ATP5B        ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide, mRNA          853.925    53.4692   −3.9973              Overexpressed and associated with poor survival in breast cancer. High ATP5B mRNA expression in ovarian cancer was associated with worse OS \[[@ref88]\]
  00000003418         MSN          Moesin (MSN), mRNA                                                                       339.836    22.2957   −3.93                High levels associated with poor breast cancer survival, by increased metastasis, invasion and EMT - changes \[[@ref89]\]
  00000008409         MYC          V-myc myelocytomatosis viral oncogene homolog (avian)                                    596.739    41.8222   −3.8347              Correlated with distant metastasis, aggressive breast cancer. Induces genome instability \[[@ref90]\]
  00000021523         STAT3        Signal transducer and activator of transcription 3 (acute-phase response factor), mRNA   566.044    39.895    −3.8266              Associated with increased angiogenesis, metastasis, immune signaling and inflammation in basal like breast - cancers \[[@ref91],[@ref92]\]
  00000008611         IGFBP4       Insulin-like growth factor binding protein 4                                             627.819    44.5065   −3.8182              Antagonist of wnt beta catenin signaling pathway, higher in metastatic RCC. Increases invasion, cell proliferation in glioma \[[@ref93],[@ref94]\]
  00000007606         HNRNPU       Heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A), mRNA           386.733    28.0595   −3.7847              Involved in spliceosome pathway in causing prostate cancer \[[@ref95]\]

EP=SCC early passage cells, HCT=SCC horn tissue, NSCLC=Non-small cell lung cancer, ITGA6=Integrin, alpha 6, AML=Acute myeloid leukemia, ATP=Adenosine triphosphate, EMT=Epithelial-mesenchymal transition, RCC=Renal cell carcinoma, SCC=Squamous cell carcinoma, FPKM=Fragments per kilobase of exon per million, *S. cerevisiae*=*Saccharomyces cerevisiae*

Discussion {#sec1-4}
==========

In this study, we compared gene expression profiles of the two conditions, i.e., *in vivo* cancer tissue and *in vitro* cancer cells at their early passages. The growth and survival rate of SCC early passage cells were good and it grew for the first few passages without difficulties. The cellular compositions were homogeneous and were of morphological characteristics typical of squamous cell epithelium. These findings are more or less similar to previously described studies \[[@ref31]\] that indicated that early passage cell cultures expressed genes similar to *in vivo* gene expression pattern. Hence, it could be used for *in vitro* investigation of transcriptomic alteration in cancers. Maximum value of differential gene expression in SCC early passage cells was 6.02-fold changes as compared to parental tissue. CCDC94 a dose-dependent modifier of the anti-apoptotic function of B-cell lymphoma 2 gene found to be up-regulated \[[@ref96]\] in SCC early passage cells; PTCH1 overexpression might indicate invasive behavior of metastatic cells \[[@ref97]\]; low Hh signaling \[[@ref98]\] ([Table-9](#T9){ref-type="table"}). PTCH-1 overexpression in many epithelial-derived cancers correlates to overexpression of other "Hh pathway" members \[[@ref99]\] and promotion of an alternate epidermal cell fate decision that potentiates SCC formation \[[@ref100]\]. Netrin 4 overexpression might have control on reduced angiogenesis and metastasis \[[@ref101]\]; high SATB homeobox 1 expression might have helped to promote cell cycle progression, proliferation, migration and increased invasive capability with strong expression of Vimentin (2750.61 FPKM) but low or lost E-cadherin (CDH1) expression - A pivotal event for epithelial to mesenchymal transition EMT \[[@ref102]\]. EIF41A, X-linked gene overexpression along with EIF2A gene (fold change −0.56) downregulation shows improved cell proliferation as EIF2A gene is a negative regulator of protein translation, RPS7 gene overexpression (fold change −0.88) might have role in cancer cell cycle proliferation and cell cycle progression in BHCC early passage cells \[[@ref103]\]. 14-3-3 gamma was not expressed in BHCC early passage cells denoting that 14-3-3 gamma might not be working at transcriptional level, but 14-3-3 theta which was found to be increased (fold change 0.30) might had a positive effect on tumor cell adhesion and growth \[[@ref104]\]. In correlation to that Stratifin or 14-3-3 sigma was not expressed in BHCC early passage cells. Cyclin D1 (FPKM in BHCC early passage cells is \~86) which usually acts as an active switch for regulation of continuous cell cycle progression, had almost same expression in two samples, revealing the possible cycle chain in between these key players. Phosphoserine phosphatase \[[@ref105]\]; inorganic pyrophosphates have a role in energy transduction, DNA replication and other metabolic processes that usually deregulate in cancer cells. It has been postulated that protein phosphatases are involved in the suppression of cellular growth and cancer development by antagonizing protein kinases in human cancers. Protein phosphatase 2 subunit B isoform alpha (PPP2R2A) is one of the four major Ser/Thr phosphatases and is a potential tumor suppressor gene \[[@ref106]\], PP2, regulatory subunit B, epsilon isoform (PPP2R5E) expression are usually downregulated in cancer tissue and represses cell viability and growth promoting apoptosis in cells as a target of MicroRNA-23a (miR-23a) \[[@ref107]\]. MiR-23a overexpression decreases PPP2R5E expression but as the cells were good and healthy by their phenotypes so we cannot support this hypothesis for our cell line. Glutaminase which indicates faster growth rate and change in Warburg effect \[[@ref108]\] was increased (0.33-fold change) (not shown in table) in cells though, MYC oncogenic transcription factor expression in BHCC early passage cells was lower than BHCC tissue, and there was no expression of MiR-23a/b which are usually suppressed by MYC \[[@ref109]\]. Solute carrier family 7A5, phosphoglycerate dehydrogenase decreased in cells, ACACA expression remained almost same, but ACLY expression was 1.5-fold lower in cells ([Table-10](#T10){ref-type="table"}). SERBP1 expression was also lower in cells by 1.5-fold. Moderate secretory carrier membrane proteins 3 expressions suggested a universal role in membrane traffic at the plasma membrane \[[@ref110],[@ref111]\].

###### 

Expression of genes that are usually altered in cancer and involved in cancer pathways.

  Official gene symbol                                   SCC horn tissue FPKM                                             SCC early passage cells FPKM                                     Log~2~ (fold change)   Official gene symbol            SCC horn tissue FPKM   SCC early passage cells FPKM   Log~2~ (fold change)   Official gene symbol             SCC horn tissue FPKM   SCC early passage cells FPKM   Log~2~ (fold change)
  ------------------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------- ------------------------------- ---------------------- ------------------------------ ---------------------- -------------------------------- ---------------------- ------------------------------ ----------------------
  Genes involved in TGF beta pathway \[[@ref114]\]       Tumor suppressor genes \[[@ref114]\]                             Apoptosis \[[@ref114]\]                                                                                                                                                                                                                                                                     
  TGFB2                                                  37.681                                                           116.199                                                          1.62466                PTCH1                           1.25528                92.8954                        6.20952                CDK2AP1                          109.22                 354.565                        1.6988
  TGFBR1                                                 43.997                                                           180.905                                                          2.03972                ZFHX4                           9.4298                 15.5071                        0.717634               CDK14                            21.499                 106.068                        2.30264
  TGFBI                                                  381.88                                                           71.3708                                                          −2.41975               SDHB                            298.285                108.237                        −1.4625                CDKN1A                           164.35                 116.955                        −0.4908
  TGFB1I1                                                81.946                                                           53.198                                                           −0.62321               TP53INP1                        109.129                15.4711                        −2.81839               TNFRSF1B                         17.236                 85.0433                        2.30275
  CTGF                                                   1237.8                                                           1486.66                                                          0.26426                TP53BP1                         21.8765                28.4023                        0.376625               TNFRSF1B                         17.236                 85.0433                        2.30275
  TGFB2                                                  37.681                                                           116.199                                                          1.62466                WTIP                            6.28321                38.751                         2.62466                TNFRSF19                         0                      64.8309                        ∞
  TERT                                                   0                                                                53.0329                                                          ∞                      STK25                           28.8784                59.3717                        1.03979                WDR44                            0                      90.9718                        ∞
  CDKs \[[@ref114]\]                                     GSTK1                                                            36.2615                                                          111.844                1.62498                         WDR45L                 89.843                         246.268                1.45474                                                                                
  CDKN1A                                                 164.35                                                           116.955                                                          −0.4908                CTSC                            337.901                48.4657                        −2.80156               WDR48                            50.640                 44.6152                        −0.1827
  CDK16                                                  59.044                                                           58.2622                                                          −0.01924               RB1                             7.81432                16.0636                        1.0396                 APAF1                            10.494                 21.5734                        1.03962
  CDK2AP1                                                109.221                                                          354.565                                                          1.6988                 RNF130                          72.5241                137.638                        0.92435                TNFAIP8L                         36.440                 89.9108                        1.30295
  CDK14                                                  21.4991                                                          106.068                                                          2.30264                ZNF189                          9.8045                 30.2333                        1.62462                TNFRSF1B                         17.236                 85.0433                        2.30275
  Genes highly expressed in cell, tumor \[[@ref114]\]    RNF11                                                            78.2997                                                          307.308                1.9726                          TNFRSF19               0                              64.8309                Infinity                                                                               
  SPARC                                                  5788.5                                                           1127.85                                                          −2.35963               RNF13                           23.1794                122.535                        2.40228                C1QTNF3                          132.88                 100.355                        −0.40511
  Genes expressed in immortal cell lines \[[@ref114]\]   CDKN1A                                                           164.35                                                           116.955                −0.49082                        TNFAIP8L1              27.853                         34.3557                0.30271                                                                                
  TOP1                                                   160.34                                                           47.6561                                                          −1.75045               SMAD4                           105.153                102.396                        −0.03833               APC pathway \[[@ref114]\]                                                              
  PCNA                                                   251.05                                                           46.9208                                                          −2.4197                Stability genes \[[@ref114]\]   LRP12                  84.539                         38.6188                −1.13031                                                                               
  CDC26                                                  0                                                                276.369                                                          Infinity               ATM                             19.4638                9.2331                         −1.07591               LRP4                             7.1667                 14.7322                        1.03959
  CDC2L1                                                 52.649                                                           30.9242                                                          −0.76769               ATMIN                           50.0996                19.9333                        −1.32962               APC                              14.067                 8.26207                        −0.7677
  CDC27                                                  37.956                                                           16.7198                                                          −1.18279               BRCA1                           20.3512                15.6881                        −0.37544               MYC                              596.73                 41.8222                        −3.8347
  Tumor suppressor genes \[[@ref114]\]                   Oncogenes \[[@ref114]\]                                          CCND1                                                            89.928                 85.3383                         −0.0755                                                                                                                                                             
  APC                                                    14.067                                                           8.26207                                                          −0.76779               MET                             4.43146                18.2192                        2.03961                                                                                                       
  Tumor suppressor genes \[[@ref114]\]                   List of genes that are usually altered in cancer \[[@ref115]\]   List of genes that are usually altered in cancer \[[@ref115]\]                                                                                                                                                                                                                              
  EXT1                                                   152.414                                                          63.7274                                                          −1.25801               KLF10                           175.839                65.7242                        −1.41976               AOX1                             26.1803                37.9893                        0.53711
  EXT2                                                   47.495                                                           92.4998                                                          0.96166                KLF5                            207.845                134.928                        −0.62332               BUB1                             15.4024                23.7471                        0.624594
  GLi pathway \[[@ref114]\]                              KLF6                                                             217.105                                                          306.05                 0.495374                        NME1                   264.994                        163.488                −0.69677                                                                               
  EXT1                                                   152.414                                                          63.7274                                                          −1.25801               TPX2                            113.49                 31.1076                        −1.86723               PCDH18                           6.99252                103.495                        3.8876
  EXT2                                                   47.495                                                           92.4998                                                          0.96166                ACAT1                           141.472                62.3266                        −1.18259               PCDH17                           3.49188                21.5346                        2.62458
  PTCH1                                                  1.2552                                                           92.8954                                                          6.20952                CDC27                           37.9565                16.7198                        −1.18279               PCDH7                            18.0213                17.098                         −0.07587
  CCND1                                                  89.928                                                           85.3383                                                          −0.0755                CDC2L1                          52.6498                30.9242                        −0.76769               ABCA3                            6.16494                30.4151                        2.30263
  PI3K pathway \[[@ref114]\]                             CDC26                                                            0                                                                276.369                ∞                               NMT1                   58.3807                        45.0079                −0.37531                                                                               
  SCAMP3                                                 135.784                                                          139.585                                                          0.03983                MCM3AP                          51.0153                28.6007                        −0.83488               PRC1                             97.9744                30.2115                        −1.69731
  NAMPT                                                  19.696                                                           69.4103                                                          1.81721                SERBP1                          565.676                213.062                        −1.4087                PTTG1IP                          207.906                122.119                        −0.76765
  AKTIP                                                  61.4721                                                          42.9791                                                          −0.5163                NRBP1                           140.308                129.802                        −0.11229               SHMT1                            20.3035                35.7767                        0.817291
  CTSC                                                   337.90                                                           48.4657                                                          −2.80156               CIRBP                           58.5565                57.7807                        −0.01924               RRM2                             81.5659                61.1926                        −0.41461
  LAMTOR5                                                65.978                                                           203.559                                                          1.62537                CDH13                           11.6941                48.0794                        2.03963                TOP1                             160.345                47.6561                        −1.75045
  LAMTOR4                                                0                                                                207.588                                                          ∞                      COL4A1                          156.377                60.2731                        −1.37544               SCFD1                            24.4279                129.136                        2.40229
  AEBP1                                                  269.61                                                           95.0153                                                          −1.50469               ENO1                            1156.36                581.125                        −0.99266               NAP1L4                           142.404                83.6444                        −0.76765
  RPS6KA4                                                26.142                                                           29.3143                                                          0.165186               RBFOX2                          68.9153                28.3343                        −1.28228               SPP1                             909.522                965.956                        0.086848
  RPS6KB1                                                69.345                                                           183.303                                                          1.40236                FOXN3                           47.44                  22.9456                        −1.04788               CCNE2                            19.4415                137.03                         2.81728
  RPS6KC1                                                27.447                                                           19.9144                                                          −0.46289               FOXJ2                           29.0679                29.878                         0.039658               CCNY                             154.802                65.8485                        −1.2332
  BCL2L13                                                12.845                                                           118.832                                                          3.20963                PRKAR1A                         534.133                67.9277                        −2.97513               TRMT10A                          4.72355                58.2622                        3.62462
  Oncogenes \[[@ref114]\]                                PRKAR2A                                                          141.262                                                          62.2342                −1.18259                        ARHGAP24               13.8698                        68.4312                2.30271                                                                                
  METTL13                                                8.588                                                            35.31                                                            2.03968                TGFBI                           381.889                71.3708                        −2.41975               New cancer genes \[[@ref115]\]                                                         
  PDGFRA                                                 55.2793                                                          12.8642                                                          −2.10337               TGFBR1                          43.9979                180.905                        2.03972                ITM2B                            731.712                364.724                        −1.00447
  Hh pathway \[[@ref114]\]                               THBS2                                                            295.379                                                          41.8762                −2.81836                        NUP205                 37.2026                        55.6184                0.580157                                                                               
  ARNTL                                                  5.52379                                                          39.7419                                                          2.84693                CKAP2                           70.1512                112.865                        0.686055               FAT1                             168.926                148.005                        −0.19075
                                                                                                                                                                                                                  UBE2C                           150.04                 142.406                        −0.07533               ITM2C                            95.1238                45.129                         −1.07575

SCC=Squamous cell carcinoma, FPKM=Fragments per kilobase of exon per million, TGF=Transforming growth factor

###### 

Genes commonly deregulated in cancer.

  Official gene symbol                               SCC horn tissue FPKM   SCC early passage cells FPKM   Log~2~ (fold change)   Official gene symbol                                          SCC horn tissue FPKM   SCC early passage cells FPKM   Log~2~ (fold change)
  -------------------------------------------------- ---------------------- ------------------------------ ---------------------- ------------------------------------------------------------- ---------------------- ------------------------------ ----------------------
  Genes up regulated in most cancers \[[@ref110]\]   IQGAP3                 13.3333                        14.9501                0.16512                                                                                                             
  ZBTB11                                             51.1437                93.4543                        0.86970                                                                                                                                    
  IPO7                                               330.60                 70.3061                        −2.2333                RPN2                                                          308.245                578.589                        0.90846
  FKBP10                                             125.032                34.2715                        −1.86721               IPO4                                                          24.7048                50.7859                        1.03964
  PRC1                                               97.974                 30.2115                        −1.69731               FARP1                                                         25.0428                57.9149                        1.20954
  FNDC3B                                             79.1106                25.3438                        −1.64224               TMEM41B                                                       35.6942                82.5496                        1.20957
  ILF3                                               79.5314                25.8148                        −1.62332               TTLL4                                                         18.5496                45.7588                        1.30266
  ACLY                                               121.74                 41.7097                        −1.54534               GEMIN6                                                        66.7981                164.81                         1.30292
  ADAM12                                             69.750                 29.6667                        −1.23336               CALU                                                          213.254                563.68                         1.4023
  PSMB2                                              315.665                139.101                        −1.1822                SNX10                                                         17.7203                72.8583                        2.03969
  EIF2AK1                                            56.6175                31.7431                        −0.8348                RBAK                                                          12.6522                93.6353                        2.88766
  NME1                                               264.99                 163.488                        −0.6967                EPRS                                                          0                      36.3044                        ∞
  ADAM10                                             58.022                 39.761                         −0.5452                PGK1                                                          0                      277.607                        ∞
  ANP32E                                             196.546                138.547                        −0.5044                WISP2                                                         0                      257.533                        ∞
  HNRPLL                                             43.4377                31.5166                        −0.4628                Commonly down regulated genes in most cancers \[[@ref110]\]                                                         
  FAM49B                                             148.32                 107.624                        −0.4627                ERBB2IP                                                       54.7664                56.29                          0.03958
  EIF2S2                                             396.41                 344.378                        −0.2030                DHRS4                                                         64.1568                65.9521                        0.03981
  KDELR3                                             213.373                202.472                        −0.0756                                                                                                                                    
  SPP1                                               909.522                965.956                        0.08684                                                                                                                                    
  UTP18                                              44.7713                50.2058                        0.16527                                                                                                                                    
  ZBTB1                                              42.3114                49.7028                        0.23228                                                                                                                                    

SCC=Squamous cell carcinoma, FPKM=Fragments per kilobase of exon per million

Cytoplasmic serine hydroxymethyltransferase 1 (SHMT1) and thymidylate synthase genes of the *de novo* thymidylate biosynthesis pathway were found to be increased in early passage cells than BHCC tissue, but SHMT2 was not expressed in cells \[[@ref110],[@ref112],[@ref113]\]. Tumor protein 53-induced nuclear protein 1, apoptosis activating factor-1 was found to be increased in BHCC early passage cells (\>1-fold change) along with effector genes such as caspase 6 (CASP6) and caspase 9 (CASP9) (\>2-fold change) but in contrast cytochrome C was not found to be expressed and the genes CASP3, CASP8 were not detected \[[@ref114]\]. The above discussion denotes a number of key players in pathogenesis of SCC of horns in bovines which showed resemblance with human cancer studies in expression profiling.

Conclusion {#sec1-5}
==========

The signaling pathway investigation in this first culture based approach revealed that many of the cancer-related pathways reported in the literatures for other carcinomas may also be held responsible for SCC of horn in bovines. Cells from bovine horn SCC surgical specimens may be adapted *in vitro* with high efficiency, independently from any clinicopathological characteristics.

Low-passage horn cancer cell lines would still closely reflect the phenotype of the horn cancer cells *in vitro* bypassing the obstacle for obtaining more detailed insights into the diversity of phenotypic and molecular changes occurring in horn cancer cells. Our result based on the pathway analysis suggested that primary culture of horn cancer *in-vitro* may serve as the model for SCC of horns in cattle.

This transcriptome-based approach demonstrates that epithelial cultures isolated from primary horn SCC retain complex characteristics of the malignant tissue. Thus, the opportunity for basic and clinical application of functional cells derived from SCC horn tissue, instead of a few immortal cell lines should not be missed.
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